Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Peptilogics Inc. is currently navigating 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, which suggests that the company must manage different sets of examiner expectations simultaneously. The workload is further divided between 2 distinct art units, indicating that the biotechnology filings cover at least two different technical sub-specialties. This split across 2 distinct art units requires the applicant to be familiar with the specific internal policies of different examination groups.
CRAIGO, WILLIAM A is the busiest examiner for this portfolio, with 1 pending office action. Because there are 4 distinct examiners for the 4 pending office actions, the prosecution risk is diversified across multiple individuals. The presence of 2 distinct art units means the company is interacting with different supervisory structures within the patent office. Managing the various examiners requires a robust tracking system to ensure that responses are tailored to each individual's previous rulings.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, WILLIAM A | 1 | 49.2% | +38.2% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| WOITACH, JOSEPH T | 1 | 49.9% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17339598 | ARTIFICIAL INTELLIGENCE ENGINE ARCHITECTURE FOR GENERATING CANDIDATE DRUGS | WOITACH, JOSEPH T | 25d overdue |
| 18948385 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | CRAIGO, WILLIAM A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17339598 | ARTIFICIAL INTELLIGENCE ENGINE ARCHITECTURE FOR GENERATING CANDIDATE DRUGS | WOITACH, JOSEPH T | 25d overdue |
| 18447414 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | KONOPELSKI SNAVEL, SARA ELIZABETH | 29d |
| 18948385 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | CRAIGO, WILLIAM A | — |
| 18606023 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | ESPINOSA, CLAUDIA EDILMA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18948385 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | CRAIGO, WILLIAM A | — | §103§112 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18606023 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | ESPINOSA, CLAUDIA EDILMA | — | §103§112DP | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18447414 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112DP | Final Rejection | 29d | Pending | Aug 10, 2023 |
| 17339598 | ARTIFICIAL INTELLIGENCE ENGINE ARCHITECTURE FOR GENERATING CANDIDATE DRUGS | WOITACH, JOSEPH T | 1687 | §101Other | Non-Final OA | 25d overdue | Pending | Jun 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial